Verition Fund Management
PBYI icon

Verition Fund Management’s Puma Biotechnology PBYI Stock Holding History

Verition Fund Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,955
Closed -$33.4K – 3627
2024
Q4 		$33.4K Buy
+10,955
New +$31.9K ﹤0.01% 3148
2018
Q4 		– Sell
-11,489
Closed -$527K – 1141
2018
Q3 		$527K Buy
+11,489
New +$554K 0.02% 820

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Verition Fund Management's PBYI Position: Q1 2025 in Review

Verition Fund Management sold out of Puma Biotechnology (PBYI) in Q1 2025, closing a stake of 10,955 shares — an estimated $33.4K sold.

Verition Fund Management first reported a position in PBYI in Q3 2018 and held it in 2 quarters. The position peaked at $527K in Q3 2018. 116 funds tracked by Wall St. Rank hold PBYI as of Q1 2025.

  • Verition Fund Management reported no remaining Puma Biotechnology position as of Q1 2025 after selling out during the quarter.
  • Verition Fund Management sold 10,955 Puma Biotechnology shares in Q1 2025, an estimated $33.4K.
  • Verition Fund Management first reported a position in Puma Biotechnology in Q3 2018 and held it in 2 quarters.
  • Verition Fund Management's Puma Biotechnology position peaked at $527K in Q3 2018.
  • 116 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2025.

Based on Verition Fund Management's 13F filing for Q1 2025, filed 15 May 2025.